635 related articles for article (PubMed ID: 28660636)
1. Pulmonary co-infections by Pneumocystis jirovecii and Aspergillus fumigatus in non-HIV patients: A report of two cases and literature review.
Markantonatou AM; Ioakimidou A; Arvaniti K; Manou E; Papadopoulos V; Kiriklidou P; Samaras K; Kioumi A; Vyzantiadis TA
Mycoses; 2017 Oct; 60(10):626-633. PubMed ID: 28660636
[TBL] [Abstract][Full Text] [Related]
2. Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.
Ye WL; Tang N; Wen YB; Li H; Li MX; Du B; Li XM
Int Urol Nephrol; 2016 Nov; 48(11):1863-1871. PubMed ID: 27351666
[TBL] [Abstract][Full Text] [Related]
3. [Pneumocystis jirovecii Pneumonia in a Patient with Interstitial Lung Disease].
Özkoç S; Alpaydın AÖ; Delibaş SB; Ergüden C; Akkoçlu A
Turkiye Parazitol Derg; 2015 Mar; 39(1):66-9. PubMed ID: 25917588
[TBL] [Abstract][Full Text] [Related]
4. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
5. Rapid and precise diagnosis of pneumonia coinfected by Pneumocystis jirovecii and Aspergillus fumigatus assisted by next-generation sequencing in a patient with systemic lupus erythematosus: a case report.
Chen Y; Ai L; Zhou Y; Zhao Y; Huang J; Tang W; Liang Y
Ann Clin Microbiol Antimicrob; 2021 Jun; 20(1):47. PubMed ID: 34174895
[TBL] [Abstract][Full Text] [Related]
6. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.
Kofteridis DP; Valachis A; Velegraki M; Antoniou M; Christofaki M; Vrentzos GE; Andrianaki AM; Samonis G
J Infect Chemother; 2014 Jul; 20(7):412-6. PubMed ID: 24767467
[TBL] [Abstract][Full Text] [Related]
7. High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy.
Ponce CA; Chabé M; George C; Cárdenas A; Durán L; Guerrero J; Bustamante R; Matos O; Huang L; Miller RF; Vargas SL
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855071
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole.
Kato H; Samukawa S; Takahashi H; Nakajima H
J Infect Chemother; 2019 Nov; 25(11):920-924. PubMed ID: 31300379
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.
Liu A; Sun R; Cao G; Liu X; Zhu H; Yang J
BMC Infect Dis; 2022 Jun; 22(1):546. PubMed ID: 35701759
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.
Salzer HJF; Schäfer G; Hoenigl M; Günther G; Hoffmann C; Kalsdorf B; Alanio A; Lange C
Respiration; 2018; 96(1):52-65. PubMed ID: 29635251
[TBL] [Abstract][Full Text] [Related]
12. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.
Thomas M; Rupali P; Woodhouse A; Ellis-Pegler R
Scand J Infect Dis; 2009; 41(11-12):862-8. PubMed ID: 19922070
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection.
Su YS; Lu JJ; Perng CL; Chang FY
J Microbiol Immunol Infect; 2008 Dec; 41(6):478-82. PubMed ID: 19255691
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: A Retrospective Cohort Study.
Yu Q; Jia P; Su L; Zhao H; Que C
BMC Infect Dis; 2017 Jun; 17(1):392. PubMed ID: 28583135
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients.
Alvarez-Martínez MJ; Miró JM; Valls ME; Mas J; de la Bellacasa JP; Sued O; Solé M; Rivas PV; de Lazzari E; Benito N; García F; Agustí C; Wilson PE; Gatell JM; Jiménez de Anta MT; Meshnick SR; Moreno A
Diagn Microbiol Infect Dis; 2010 Sep; 68(1):60-5. PubMed ID: 20727472
[TBL] [Abstract][Full Text] [Related]
16. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and prevalence of dihydropteroate synthase gene mutations in Pneumocystis jirovecii-infected AIDS patients from low endemic areas of China.
Zhu M; Ye N; Xu J
PLoS One; 2020; 15(9):e0238184. PubMed ID: 32911508
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis jirovecii pneumonia in Latin America. A public health problem?
Calderón EJ; de Armas Y; Panizo MM; Wissmann G
Expert Rev Anti Infect Ther; 2013 Jun; 11(6):565-70. PubMed ID: 23750728
[TBL] [Abstract][Full Text] [Related]
19. Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIV-infected patients: a retrospective case control study.
Hammarström H; Grankvist A; Broman I; Kondori N; Wennerås C; Gisslen M; Friman V
BMC Infect Dis; 2019 Jul; 19(1):658. PubMed ID: 31337356
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway.
Grønseth S; Rogne T; Hannula R; Åsvold BO; Afset JE; Damås JK
BMC Infect Dis; 2021 Jul; 21(1):659. PubMed ID: 34233631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
